Search Results
Your search for ,itS matches 8761 pages
Showing 2301 - 2350Enfortumab Vedotin Represents a Community of Work in Antibody-Drug Conjugates Targeting Cancer
The first known clinical trial report of an antibody-drug conjugate was a phase 0/I pharmacodynamic and safety study of a conjugate that targeted carcinoembryonic antigen and delivered a payload of vinca alkaloid in eight patients with ovarian or colorectal cancer.1 This work built on the work of...
The Wistar Institute Recruits Noam Auslander, PhD, as Assistant Professor
The Wistar Institute, an international biomedical research leader in cancer, immunology, and infectious diseases, recently announced the appointment of Noam Auslander, PhD, as Assistant Professor in the Molecular and Cellular Oncogenesis Program of The Wistar Institute Cancer Center. Dr....
Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
On May 20, 2021, nivolumab was approved for adjuvant treatment of patients with completely resected esophageal or gastroesophageal junction (GEJ) cancer with residual pathologic disease after neoadjuvant chemoradiotherapy.1,2 Supporting Efficacy Data Approval was based on findings from the...
Is There a Link Between Use of Antibiotics and Early-Onset Colorectal Cancer?
Study findings presented by Perrott et al at the ESMO World Congress on Gastrointestinal Cancer (Abstract SO-25) showed that the use of antibiotics may be linked to colon tumor formation across all patient age groups, especially in those younger than 50 years. These results raise fresh concerns...
Study Finds Reduced Treatment Delays for Patients With Breast Cancer May Improve Survival Rates
Research published by Pratt et al in Annals of Surgical Oncology showed an increase in survival rates when treatment options—surgery, chemotherapy, and radiation—are completed within 38 weeks from the time of diagnosis for patients with breast cancer. Optimal Treatment Duration The observational...
Study Explores Co-occurring Mutations in HER2 and HER3
Mutations in a gene related to HER2, a gene frequently implicated in breast cancers and a variety of other malignancies, can amplify activity that spurs tumor growth, according to a new study. The findings, published by Hanker et al in Cancer Cell, could explain why many patients with HER2...
Predicting Chemotherapy Resistance in Patients With Gestational Trophoblastic Neoplasia
In a retrospective cohort study reported in The Lancet Oncology, Braga et al identified metastatic disease, choriocarcinoma histology, and higher pretreatment human chorionic gonadotropin concentration as independent predictors of resistance to single-agent chemotherapy in women with low-risk...
Personalizing Treatment of Early HER2-Positive Breast Cancer
With several pivotal trials providing evidence for the escalation and de-escalation of anti-HER2 therapy in certain early breast cancer scenarios, personalized treatment is possible. How can clinicians optimize treatment by applying the studies’ findings? Debu Tripathy, MD, Professor and Chair of...
Study Examines Mechanisms of Resistance in Early-Stage Breast Cancer After Endocrine Plus CDK4/6 Therapy
About 80% of breast cancer cases are hormone receptor–positive, according to the American Cancer Society. Patients with estrogen receptor–positive breast cancer generally are treated using therapy that inhibits both estrogen levels and cell-cycle activity, but about 90% of patients with metastatic...
Biden Administration Reverses Rule Limiting Access to Equitable Cancer Care for Sexual and Gender Minority Community
On May 10, 2021, the Department of Health and Human Services’ (HHS) Office for Civil Rights announced that its ban on sex discrimination once again includes a ban on discrimination on the basis of sexual orientation and gender identity. The move will reverse a final rule from June 2020 that...
New ASCO Journal Series Examines Disparities in Cancer Care for Black People in the United States
A new special series in JCO Oncology Practice explores the causes of disparities in cancer care and outcomes for Black people in the United States and examines potential solutions to begin to achieve health equity for this population. The “Disparities in Cancer Care for Black People in the United...
Emerging Reasons for Optimism in Lung Cancer
Despite public smoking cessation initiatives and improved methods for early detection and treatment, lung cancer persists as the leading cause of cancer death in both men and women in the United States. However, over the past decade, smoking cessation efforts, increased screening, and new...
PI3K Inhibition With Copanlisib Plus Rituximab in Relapsed Indolent Non-Hodgkin Lymphoma
Better understanding of the mechanism behind the malignant transformation of B cells has led to an explosion of “targeted” therapy. With the growing knowledge of the role of the B-cell receptor and its downstream kinases, it appeared that we were entering a new era in the management of patients...
Expert Point of View: Kunle Odunsi, MD, PhD, and Lilian T. Gien, MD, MSc
Comments on the OUTBACK trial were provided by invited discussant Kunle Odunsi, MD, PhD, Professor of Obstetrics and Gynecology, Dean for Oncology, and Director of the University of Chicago Medicine Comprehensive Cancer Center. Lilian T. Gien, MD, MSc, Associate Professor of Oncology at the...
Addressing Sexuality Challenges Throughout the Cancer Care Continuum
Multiple studies have shown that sexuality and intimacy problems are common among patients with cancer, often beginning at the time of diagnosis and persisting through the continuum of care into the survivorship setting. Although these problems have been well documented, many patients and survivors ...
MD Anderson and Broad Institute Launch New Translational Research Platform Focused on Rare Cancers
The University of Texas MD Anderson Cancer Center and the Broad Institute of MIT and Harvard recently announced the launch of a new translational research platform to study rare cancers and develop a first-of-its-kind resource for the scientific community. The joint initiative will create a catalog ...
John D. Carpten, PhD, FAACR, to Join the AACR Board of Directors
The American Association for Cancer Research (AACR) recently announced that John D. Carpten, PhD, FAACR, has been elected by the association to serve on its Board of Directors. Dr. Carpten has accepted the position previously held by Karen E. Knudsen, MBA, PhD, who is stepping down to fulfill her...
Innovator in Treatment of Infectious Diseases, Francisco Marty, MD, Dies at 53
The Brigham and Women’s hospital community mourns the loss of Francisco Marty, MD, of the Division of Infectious Diseases, who died April 8, 2021, after a tragic accident while hiking in the Dominican Republic. He was 53. A member of the Brigham community for more than 20 years, Dr. Marty is...
Do Community Oncologists Have Access to Geriatric Specialty Care for Older Patients?
As our population rapidly ages, the burden of cancer incidence increases accordingly, creating an urgent need for greater and more incisive research on the diagnosis, treatment, and survivorship issues for older adults with cancer. Given the numerous challenges faced by today’s busy oncologists, a...
Cancer in Morocco: Access to Innovative Treatments and Research Status
Morocco is an Arab country in North Africa. It covers 716,550 square kilometers and has a population of nearly 36 million. The median age is 29.3 years. Morocco’s estimated gross domestic product (GDP) in 2019 was $122 million. As of 2019, Morocco’s health budget was equivalent to 4.5% of the total ...
AACR CEO Margaret Foti, PhD, MD (hc), to Receive Gallery of Success Award From Temple University
Margaret Foti, PhD, MD (hc), Chief Executive Officer (CEO) of the American Association for Cancer Research (AACR), has been selected as a Temple University Gallery of Success honoree for 2021. Each year, Temple University showcases exceptional alumni from its 17 schools and colleges in its Gallery...
Chanita Hughes-Halbert, PhD, to Advance Cancer Equity at USC Norris Comprehensive Cancer Center
Chanita Hughes-Halbert, PhD, will join the University of Southern California (USC) Norris Comprehensive Cancer Center as Associate Director for Cancer Equity, a newly created position, and the Keck School of Medicine of USC as Professor and Vice Chair of Research in the Department of Preventive...
Mary Daly, MD, PhD, FACP, Receives NCCN’s 2021 Rodger Winn Award
The National Comprehensive Cancer Network (NCCN) recently presented Mary B. Daly, MD, PhD, FACP, Professor in the Department of Clinical Genetics and Director of the Risk Assessment Program at Fox Chase Cancer Center, with the Rodger Winn Award. The Rodger Winn Award is given annually to one NCCN...
Harnessing a Worldwide Effort to Combat COVID-19 and Cancer
This past October, in a virtually held ceremony of the General Assembly of the Union for International Cancer Control (UICC), Anil K. D’Cruz, MBBS, MS, DNB, FRCS (Hon), Director of Oncology at Apollo Hospitals in Mumbai, Chennai, and Delhi, India, began his 2-year tenure as President of the global...
How RAS Mutations in Early-Onset Colorectal Cancer May Impact Patient Survival
Although both incidence and mortality rates in colorectal cancer have been declining among people older than 65 by 3.3% and 3% annually, respectively, among individuals younger than age 50, the incidence rate has risen about 2% annually, and death rates have increased by 1.3% annually.1 Colorectal...
Study Explores Taste and Smell Dysfunction in Head and Neck Cancer Survivors
Most survivors of head and neck squamous cell cancers report that their sense of taste is dulled, changed, or lost during radiation treatment. In a study of taste and smell dysfunction in 40 cancer survivors, scientists found that the tips of these individuals' tongues were significantly less...
Survival of Patients With Colon Cancer Enrolled in the U.S. Military Health System
A study by Lin et al comparing patients with colon cancer enrolled in the U.S. Military Health System, which provides universal health-care to its beneficiaries, with those in the general population has found that patients in the Military Health System had an 18% lower risk of death compared with...
FDA Pipeline: Priority Reviews in Multiple Myeloma, Cervical Cancer, Neutropenia, and Myelofibrosis
Over the past month, the U.S. Food and Drug Administration (FDA) has granted Priority Review to therapies for multiple myeloma, cervical cancer, chemotherapy-induced neutropenia, and myelofibrosis. The FDA also granted a number of Breakthrough Therapy designations, including those for treatments in ...
FDA Oncology Center of Excellence Launches National Black Family Cancer Awareness Week
The U.S. Food and Drug Administration (FDA)'s Oncology Center of Excellence (OCE) has announced its inaugural National Black Family Cancer Awareness Week, which is taking place from June 17 through June 23, 2021. Throughout the week, the agency’s social media platforms will serve as the hub for...
Nearly Half of Surveyed Patients With Gynecologic Cancer Report Experiencing Financial Toxicity
In a new study designed to provide a more comprehensive picture of how a diverse cohort of patients with gynecologic cancer are affected by financial distress, nearly half reported financial toxicity, which was associated with economic cost-coping strategies. These findings were reported by Esselen ...
Senators Richard Burr and Ben Cardin Recognized as ASCO Congressional Champions for Cancer Care
ASCO has presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients....
Dual Immune Checkpoint Blockade With Nivolumab and Ipilimumab for Treatment of Malignant Pleural Mesothelioma
In recent years, immune checkpoint inhibitors in the treatment of mesothelioma have been a keen area of investigation for this immunogenic solid tumor. With recent publications, principally findings from CheckMate 743 by Baas et al1 (reviewed in this issue of The ASCO Post), combination immune...
Carol L. Prives, PhD, FAACR, Receives 2021 AACR–G.H.A. Clowes Award for Outstanding Basic Cancer Research
The American Association for Cancer Research (AACR) presented Carol L. Prives, PhD, FAACR, with the 2021 AACR–G.H.A. Clowes Award for Outstanding Basic Cancer Research during the virtual AACR Annual Meeting 2021. Dr. Prives, the Da Costa Professor of Biology in the Department of Biological Sciences ...
Selected Poster Presentations From the NCCN 2021 Annual Conference
Although once again, the National Comprehensive Cancer Network® (NCCN®) 2021 Annual Conference could not take place on site in Orlando, researchers presented their work virtually in the form of almost 100 posters. The ASCO Post has summarized some that we found particularly interesting. Many...
The Brooklyn Cancer Center Announces New Chief of Hematology and Medical Oncology
The Brooklyn Cancer Center has named hematologist-oncologist Maxim Shulimovich, DO, as its new Chief of Hematology and Medical Oncology. His recruitment promises to lead the cancer center as a unified division to provide expert care and culturally sensitive services for patients with all types of...
Roswell Park Immunologist Promoted to Endowed Chair Role
Following a national search, Roswell Park Comprehensive Cancer Center has promoted Pawel Kalinski, MD, PhD, to Jacobs Family Endowed Chair of Immunology, Chief of the Division of Translational Immuno-Oncology, and Senior Vice President for Team Science. On staff at Roswell Park since 2017, Dr....
National Advocacy Organization, Children’s Cancer Cause, Invites Applications for 2021 Survivorship Champion’s Prize
The Children’s Cancer Cause is now accepting applications for its 2021 Survivorship Champion’s Prize. The annual award was established in 2020 to recognize a group, program, or institution making significant advances in programs and services to provide lifelong health maintenance for survivors of...
Data Analysis on Early-Onset Colorectal Cancer Sheds Light on the Rising Rates in Young Adults
In May 2021, the U.S. Preventive Services Task Force (USPSTF) announced that it was updating its recommendation for when individuals at average risk of colorectal cancer should begin screening. Echoing the recommendation from the American Cancer Society in 2018, the USPSTF now recommends that those ...
Global Responses to COVID-19 Pandemic–Related Disruptions in Cancer Care
COVID-19 pandemic–related disruptions in cancer diagnosis, treatment, and research have varied worldwide and so have the responses to those disruptions. During the Society of Surgical Oncology (SSO) 2021 International Conference on Surgical Cancer Care, members of the Global Forum of Cancer...
Adjuvant Imatinib Therapy Offers Survival Benefit in Patients With Resected GIST, but Team Effort May Be Needed to Reduce Early Discontinuation Rates
Clinical trial data show that adjuvant imatinib improves recurrence-free survival as well as overall survival, when administered for at least 3 years, among patients who undergo a macroscopically complete resection of a primary gastrointestinal stromal tumor (GIST), Chandrajit P. Raut, MD, MSc,...
Adding Targeted Agent to Treatment Shows Significant Benefits in Pediatric Patients With High-Risk Hodgkin Lymphoma
Integrating the antibody-drug conjugate brentuximab vedotin into the front-line treatment of pediatric patients with high-risk Hodgkin lymphoma “facilitated significant reduction in radiation exposure and yielded excellent outcomes,” Monika Metzger, MD, MSc, Director for the Central and South...
The Ohio State Recruits Marcos J. de Lima, MD, to Lead Blood and Marrow Transplant and Cellular Therapy Programs
The Ohio State University Comprehensive Cancer Center–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC–James) has recruited Marcos J. de Lima, MD, to lead its Blood and Marrow Transplant and Cellular Therapy programs, two key leadership positions within central...
Eduardo M. Sotomayor, MD, to Lead New Tampa General Hospital Cancer Institute
Tampa General hospital recently announced the appointment of Eduardo M. Sotomayor, MD, as Director of its newly established Cancer Institute. A pioneer in the field of cancer immunology and immunotherapy and an expert in lymphoma research and treatment, Dr. Sotomayor will lead a team of Tampa...
Update on Clinical Trials in Acute Myeloid Leukemia
To complement The ASCO Post’s continued comprehensive coverage of the 2020 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on acute myeloid leukemia (AML), such as the use of venetoclax added to...
Choice of First-Line Platinum Chemotherapy Does Not Significantly Impact Efficacy of Second-Line Immunotherapy in Advanced Urothelial Carcinoma
In a presentation of real-world data given during the 2021 ASCO Annual Meeting, Miron et al concluded that the choice of first-line platinum chemotherapy did not result in a significant difference in overall survival benefit among patients with advanced bladder cancer who were able to go on to...
Omid Hamid, MD, Discusses RELATIVITY-047
Omid Hamid, MD, Chief of Translational Research/Immuno-Oncology at The Angeles Clinic & Research Institute, Los Angeles, and Co-Director of the Cutaneous Malignancy Program at Cedars-Sinai Cancer Institute, shared his thoughts on the RELATIVITY-047 study1 for The ASCO Post, referring to them as ...
Targeting LAG-3 and PD-1 With Relatlimab and Nivolumab: A New Option Under Study in Advanced Melanoma
Immune checkpoint inhibition has been established as an effective treatment for patients with metastatic melanoma. A novel immunotherapeutic combination—this one targeting the LAG-3 (lymphocyte-activation gene 3) and PD-1 immune checkpoints—delayed time to disease progression significantly more...
High-Dose Interferon or Ipilimumab vs Pembrolizumab for High-Risk Resected Melanoma
Patients with high-risk melanoma who had a course of pembrolizumab had longer recurrence-free survival than patients who received either ipilimumab or high-dose interferon after surgery. These findings of a large SWOG Cancer Research Network clinical trial, S1404, were presented by Grossmann et al...
Novel PSMA-Targeted Radiotherapy Improves Radiographic Progression-Free and Overall Survival in Metastatic Prostate Cancer
Lutetium-177–PSMA-617 (Lu-177–PSMA-617)—an investigational radioligand therapy—significantly improved radiographic progression-free survival and overall survival when added to standard of care compared with standard of care alone for men with metastatic castration-resistant prostate cancer whose...
Study Examines Relationship Between Risk of COVID-19 Infection and Breast Cancer Treatment
In a study led by researchers at NYU Langone Health and its Perlmutter Cancer Center involving more than 3,000 women treated for breast cancer at the height of the COVID-19 pandemic in New York City, only 64 patients, or 2% of the total study population, contracted the virus. Of this group, 10 died ...
